Research funder · United States

Michael J. Fox Foundation for Parkinson's Research

Non-profit organization in the USA

michaeljfox.org

Grants since 2016: 1 275
Awarded, last 5 years (where amounts are published): —
Funded works, last 5 years: 3 085
Funded works, all time: 6 716

Grants

2021 · research · Aligning Science Across Parkinson's

Circuit Mechanisms for Dopamine Neuron Vulnerability and Resilience in Parkinson’s Disease

William C. Mobley · University of California San Diego

2021 · research · Fall 2021 RFP: Expanding Biological Understanding of PD

Characterizing the Impact of a Protective LRRK2 Variant on Biochemical and Cellular Function

Patrick A. Lewis · UCL Queen Square Institute of Neurology

2021 · research · PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development

Development of Selective Markers for Imaging Abnormal Protein Aggregates in Parkinson’s Disease

Armin Giese · Modag Gmbh

2021 · research · Research Grant

Codevelopment of Small-molecule Regulators of Miro1 for the Treatment of Parkinson’s Disease and a GLP Clinical Biomarker Assay

William Dvořák Shrader · Acurex Therapeutics Corporation

2021 · research · MJFF Funded Study

Evaluating Patient-reported Outcome Assessment in Early Parkinson’s Disease

Glenn Stebbins · Rush University

2021 · research · Improved Biomarkers and Clinical Outcome Measures

Isolating Olfactory Biomarkers of Early Parkinson’s Disease

Marianna Cortese · Harvard University

2021 · research · Environmental Risk Factors

Pesticide Exposure, Systems Biology and Parkinson’s Disease

Beate Ritz · University of California, Los Angeles

2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Impact of TRPML1 Stimulation on Clinical Biomarkers and Synuclein Pathology

Magdalene M. Moran · Caraway Therapeutics, Inc.

2021 · research · Research Grant

Hypoxia (Limiting Oxygen Levels) as a Novel Treatment for Parkinson’s Disease

Bastiaan R. Bloem · Radboud University Medical Center

2021 · research · Biosample Use Program

Evaluating Neurotoxic Metabolites as Biomarkers of Parkinson’s Progression

Lena Cecilia Brundin · Center For Neurodegenerative Science; Van Andel Research Institute

2021 · research · Therapeutic Pipeline Program

Compounds that Enhance the Activity of GCase as a Treatment for Parkinson’s Disease

Jean-François Blain · Arkuda Therapeutics

2021 · research · Analysis of Patient-Reported Outcomes from Fox Insight

Investigation of Environmental Factors in Idiopathic and LRRK2-related Parkinson’s Disease

Joanne Trinh · University of Lübeck

2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)

Caryl E. Sortwell · Michigan State University

2021 · research · Environmental Risk Factors

Nationwide Geographic Cluster Analysis of Incident Parkinson’s Disease

Susan Searles Nielsen · Washington University in St. Louis

2021 · research · Fall 2021 RFP: Outcome Measures

Characterization of Sterols in CSF and Plasma as a Possible Biomarker for Parkinson’s Disease

William James Griffiths · Swansea University

2021 · research · Therapeutic Pipeline Program

Studies to Assess the Potential of Gold “Nanocrystals” for the Treatment of Parkinson’s Disease

Karen S. Ho · Clene Nanomedicine, Inc.

2021 · research · Analysis of Patient-Reported Outcomes from Fox Insight

Overcoming Underrepresentation to Improve Generalizability in Fox Insight

Ali G. Hamedani · University of Pennsylvania

2021 · research · Therapeutic Pipeline Program

Using Virtual Reality to Understand and Treat Freezing of Gait

Jay L. Alberts · Cleveland Clinic

2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Development of Novel Brain-penetrant Inflammasome Inhibitors as Potential Therapeutics for Parkinson’s Disease

Tamara Seredenina · AC Immune (Switzerland)

2021 · research · Target Advancement Program

Pathogenic Mechanisms for Auxilin-mediated Parkinson's Disease

Sreeganga S. Chandra · Yale University

2021 · research · Fall 2021 RFP: Outcome Measures

Exploring the Role of Faulty Protein Degradation as a Cause of Parkinson’s Disease

Karteek Kadimisetty · LifeSensors (United States)

2021 · research · Therapeutic Pipeline Program

Pharmacological Targeting of Inflammation to Modify Disease Progression in Pre-clinical Models of Parkinson’s Disease

Arthi Kanthasamy · University of Georgia

2021 · research · Biomarkers

Measurement of Mitochondrial DNA in Early Stages of Parkinson’s Disease

Ramon Trullas · Institute For Biomedical Research Of Barcelona, Iibb/csic, Ciberned

2021 · research · Aligning Science Across Parkinson's

Olfactory Circuits: Alpha-Synuclein-Rich Neurons Respond to Environmental Triggers at the Origin of Parkinson’s Disease

Michael G. Schlossmacher · Ottawa Hospital

2021 · research · Priority Biology

LRRK2 Regulation of Melanoma Progression

Deanna L. Benson · Icahn School of Medicine at Mount Sinai

2021 · research · Target Advancement Program

Targeting the Body’s Circadian Clock to Improve Sleep Quality in Parkinson’s Disease

Oliver Rawashdeh · The University of Queensland

2021 · research · Research Grant

Hidden Sorrows of Covid-19: Impact of Stress on Parkinson’s Disease Progression

Rick C.G. Helmich · Radboud University Nijmegen

2021 · research · Target Advancement Program

Exploring How a Chemical Produced by Intestinal Microbes Contributes to the Pathology and Progression of Parkinson's Disease

Richard Gordon · Queensland University of Technology

2021 · research · Aligning Science Across Parkinson's

Alpha-synuclein Effects on Gut-brain Circuits and Pre-motor Symptoms in Parkinson’s Disease

Michael Gordon Kaplitt · Weill Cornell Medicine

2021 · research · Target Advancement Program

SCARB2 as a Potential Target in Parkinson’s Disease

Ziv Gan-Or · McGill University

2021 · research · Expanding Biological Understanding of PD

Assessing Inhibition of NLRP3 to Reduce Brain Inflammation in Parkinson’s Disease

Matthew C. Havrda · Dartmouth College

2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Establishing the Therapeutic Potential of Engineered Neural Circuits in a Preclinical Model of Parkinson’s Disease

D. Kacy Cullen · Veterans Health Administration

2021 · research · Therapeutic Pipeline Program

Targeting Brain-specific Stearoyl-CoA-Desaturase 5 (SCD5) as a Treatment for Parkinson’s Disease

Lan T. H. Dang · Alnylam Pharmaceuticals (United States)

2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease

Johan Lundkvist · Sinfonia Biotherapies Ab

2021 · research · Biomarkers